Adlai Nortye Receives FDA Clearance For AN4035 Phase I Trial

Adlai Nortye dosed the first patient in Australia in its global Phase I trial of AN4035 and received U.S. FDA clearance to expand the study. The first-in-class CEACAM5-targeting ADC delivers a pan-RAS(ON) inhibitor payload to RAS-addicted tumors.